By tagging its antibody with a molecular key that unlocks the barrier, Roche’s trontinemab quickly permeates the brain. The ...
After almost 18 years of collaboration, Roche’s Genentech unit has ended a collaboration with AC Immune on Alzheimer’s disease therapies, handing back rights to two antibody-based drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback